ELVN
Enliven Therapeutics, Inc. NASDAQ Listed Mar 12, 2020$46.83
+3.83%
vs $45.10
Mkt Cap $3.3B
52w Low $14.79
95.0% of range
52w High $48.53
50d MA $41.75
200d MA $28.23
P/E (TTM)
—
EV/EBITDA
—
P/B
5.8x
Debt/Equity
0.0x
ROE
-22.6%
P/FCF
-36.3x
RSI (14)
60.60
ATR (14)
$3.13
Beta
0.49
50d MA
$41.75
200d MA
$28.23
Avg Volume
1.4M
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
6200 Lookout Road · Boulder, CO 80301 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | -0.42 | -0.48 | -14.3% | 28.75 | -0.6% | +4.3% | -2.3% | +0.5% | +1.0% | +1.7% | — |
| Nov 12, 2025 | AMC | -0.43 | -0.32 | +25.6% | 20.30 | +0.0% | -0.1% | +8.9% | -1.4% | +3.8% | -2.2% | — |
| Aug 13, 2025 | AMC | -0.53 | -0.49 | +7.5% | 19.99 | -0.3% | -1.1% | +2.3% | -2.3% | +0.1% | -0.5% | — |
| May 14, 2025 | AMC | -0.51 | -0.57 | -11.8% | 19.89 | -2.3% | -10.4% | -5.4% | -0.1% | +3.1% | -2.6% | — |
| Mar 13, 2025 | AMC | -0.53 | -0.46 | +13.2% | 20.29 | +4.0% | +2.2% | +1.4% | -3.6% | +3.0% | +0.1% | — |
| Nov 13, 2024 | AMC | -0.52 | -0.48 | +7.7% | 25.80 | +2.2% | -3.4% | -2.0% | +2.0% | +5.1% | -2.9% | — |
| Aug 13, 2024 | AMC | -0.58 | -0.41 | +29.3% | 21.52 | +4.3% | +1.3% | +9.0% | -0.3% | -0.8% | -5.2% | — |
| May 14, 2024 | AMC | -0.58 | -0.54 | +6.9% | 23.87 | +4.1% | +0.5% | -0.8% | -3.2% | +4.2% | -4.6% | — |
| Mar 14, 2024 | AMC | -0.56 | -0.47 | +16.1% | 11.54 | -3.6% | +3.7% | +5.6% | +38.8% | +9.5% | -6.0% | — |
| Nov 9, 2023 | AMC | -0.49 | -0.51 | -4.1% | 11.55 | +0.1% | -1.5% | -4.2% | +0.9% | -0.5% | -4.8% | — |
| Aug 10, 2023 | AMC | -0.40 | -0.41 | -2.5% | 17.52 | -1.4% | +0.1% | -6.2% | +0.1% | -6.9% | +6.0% | — |
| May 11, 2023 | AMC | -0.67 | -0.80 | -19.4% | 19.10 | -0.5% | +1.6% | +2.2% | -0.1% | +0.9% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 9 | Stifel | Initiates | Buy | $60 | $33.63 | $34.62 | +2.9% | +7.4% | +2.5% | +9.1% | +14.3% | -8.2% |
| May 12 | Guggenheim | Initiates | Buy | $80 | $39.59 | $40.65 | +2.7% | +6.8% | +3.0% | -1.1% | -4.0% | -4.1% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.53 | $35.66 | +0.4% | +10.6% | -1.2% | -5.8% | +7.1% | -3.6% |
| Mar 25 | Mizuho | Maintains | Outperform → Outperform | — | $31.15 | $33.76 | +8.4% | +14.1% | +10.6% | -1.2% | -5.8% | +7.1% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.65 | $20.04 | +2.0% | +5.0% | +0.4% | -5.5% | +1.7% | +8.3% |
| Jun 16 | Baird | Maintains | Outperform → Outperform | — | $21.91 | $23.38 | +6.7% | +5.4% | -5.6% | -1.1% | -1.3% | -4.7% |
| May 16 | Jones Trading | Maintains | Buy → Buy | — | $17.82 | $17.73 | -0.5% | -5.4% | -0.1% | +3.1% | -2.6% | -0.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.89 | $19.44 | -2.3% | -10.4% | -5.4% | -0.1% | +3.1% | -2.6% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.92 | $20.64 | -1.3% | +0.8% | +6.5% | -5.1% | -3.5% | +4.5% |
| Nov 15 | Baird | Maintains | Outperform → Outperform | — | $24.92 | $25.00 | +0.3% | -2.0% | +2.0% | +5.1% | -2.9% | -0.1% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.54 | $25.70 | +0.6% | +1.8% | -2.7% | +0.8% | +7.9% | -0.3% |
| Mar 29 | Jefferies | Maintains | Buy → Buy | — | $23.49 | $23.75 | +1.1% | +2.0% | -7.6% | -1.1% | +1.1% | +2.7% |
| Mar 3 | TD Cowen | Maintains | Outperform → Outperform | — | $23.45 | $24.80 | +5.8% | -5.8% | -1.0% | -3.2% | +5.9% | -5.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 272,322 | $45.02 | $12.3M | 7,388,902 | +0.54% | — |
| Jun 15, 2026 | ORBIMED ADVISORS LLC10% | — | Sell | 9,086 | $45.02 | $409K | 245,728 | +0.54% | — |
| Jun 5, 2026 | Kunkel Lori Anne | — | Sell | 354 | $35.82 | $13K | 51,884 | +2.46% | +0.45% |
| Jun 5, 2026 | Kunkel Lori Anne | — | Sell | 1,867 | $35.36 | $66K | 52,238 | +2.46% | +0.45% |
| Jun 5, 2026 | Kunkel Lori Anne | — | Sell | 7,779 | $34.28 | $267K | 54,105 | +2.46% | +0.45% |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 223 | $41.21 | $9K | 25,000 | +0.93% | -1.84% |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 1,302 | $40.25 | $52K | 25,223 | +0.93% | -1.84% |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 3,475 | $39.53 | $137K | 26,525 | +0.93% | -1.84% |
8-K · 7.01
! Medium
Enliven Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 11
8-K · 5.03
! Medium
Enliven Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 10
8-K
Enliven Therapeutics, Inc. -- 8-K Filing
Enliven Therapeutics (ELVN) is advancing ELVN-001 toward Phase 3 trials with a pivotal data readout and regulatory interactions planned for 2026, signaling potential milestone catalysts ahead.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 6,829,246 | $268M | Reduced | Mar 2026 |
| 2 | Bellevue Group Ag | 2,320,867 | $91M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,168,162 | $85M | New | Mar 2026 |
| 4 | Fairmount Funds Management Llc | 1,855,644 | $73M | Reduced | Mar 2026 |
| 5 | Citadel Advisors Llc | 1,743,915 | $68M | Added | Mar 2026 |
| 6 | Vr Adviser, Llc | 3,226,331 | $50M | — | Dec 2025 |
| 7 | Jones Hill Capital Lp | 593,040 | $23M | New | Mar 2026 |
| 8 | Pictet Asset Management Holding Sa | 1,303,235 | $20M | Reduced | Dec 2025 |
| 9 | Avidity Partners Management Lp | 400,000 | $16M | New | Mar 2026 |
| 10 | Northern Trust Corp | 372,316 | $15M | Added | Mar 2026 |
| 11 | Capricorn Fund Managers Ltd | 369,400 | $14M | New | Mar 2026 |
| 12 | Stempoint Capital Lp | 363,438 | $14M | New | Mar 2026 |
| 13 | Millennium Management | 345,318 | $14M | Added | Mar 2026 |
| 14 | Vanguard Portfolio Management Llc | 330,964 | $13M | New | Mar 2026 |
| 15 | Adar1 Capital Management, Llc | 329,540 | $13M | New | Mar 2026 |
| 16 | Morgan Stanley | 823,646 | $13M | Added | Dec 2025 |
| 17 | Vanguard Fiduciary Trust Co | 312,763 | $12M | New | Mar 2026 |
| 18 | Woodline Partners Lp | 301,673 | $12M | — | Mar 2026 |
| 19 | Ubs Group Ag | 283,544 | $11M | Added | Mar 2026 |
| 20 | Soleus Capital Management, L.p. | 230,869 | $9M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.27B
Enterprise Value
$2.09B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
2.65x
P/B
5.77x
P/S
—
P/FCF
-36.27x
EV/EBITDA
—
Shares Out
56.7M
Financials (TTM)
Revenue
$0
Net Income
-$98.8M
EBITDA
-$98.6M
Free Cash Flow
-$70.5M
Op Cash Flow
-$70.3M
EPS Basic
$-1.83
EPS Diluted
$-1.64
EPS Forward
$-2.02
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$476.2M
Total Liab.
$16.7M
Total Equity
$459.6M
Cash
$462.6M
LT Debt
$0
Book Value/Sh
$8.11
Debt/Equity
0.00x
Current Ratio
28.66
Quick Ratio
28.66
Returns & Growth
ROE
-22.6%
ROA
-21.8%
ROIC
-26.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+3.2%
Price Returns
2W
-8.1%
1M
-4.0%
3M
+33.3%
6M
+83.2%
12M
+122.7%
Technicals
52W High
$48.53
52W Low
$14.79
50d MA
$41.75
200d MA
$28.23
RSI (14)
60.60
ATR (14)
$3.13
Beta
0.49
Avg Volume
1.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$43.33
High
$52.00
Low
$39.00
Median
$39.00
Data updated apr 25, 2026 7:00am
· Source: financialmodelingprep.com